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Abstract: Background: Despite being a highly prevalent disease and a possible contributor to adult
tooth loss, periodontitis possesses no well-established therapy. The aim of the recent study was the
development and evaluation of a mucoadhesive monophase lipid formulation for the sustained
local delivery of amoxicillin, metronidazole, and/or zinc hyaluronate or gluconate. Methods:
To investigate our formulations, differential scanning calorimetry, X-ray diffraction, swelling, erosion,
mucoadhesivity, drug release, and antimicrobial measurements were performed. Results: Differential
scanning calorimetry (DSC) and X-ray diffraction (XRD) results show that the loaded drugs are in a
suspended form, the softening of the formulations starts at body temperature, but a part remains
solid, providing sustained release. Swelling of the lipid compositions is affected by the hydrophilic
components, their concentration, and the strength of the coherent lipid structure, while their
erosion is impacted by the emulsification of melted lipid components. Conclusions: Results of
drug release and antimicrobial effectiveness measurements show that a sustained release may be
obtained. Amoxicillin had higher effectiveness against oral pathogens than metronidazole or zinc
hyaluronate alone, but the combination of the two latter could provide similar effectiveness to
amoxicillin. The applied mucoadhesive polymer may affect adhesivity, drug release through the
swelling mechanism, and antimicrobial effect as well.
Keywords: periodontitis; lipid drug delivery; zinc hyaluronate; amoxicillin; metronidazole
1. Introduction
The plaque-induced forms of periodontal diseases are the most prevalent chronic inflammatory
conditions seen in humans worldwide, affecting nearly half of the adults. Periodontitis is a major
health problem reducing the quality of life. Not only does it cause tooth loss, disability, masticatory
dysfunction, poor nutritional status, and compromised speech, but it is also independently associated
with systemic chronic inflammatory diseases including atherogenic cardiovascular disease, type 2
diabetes mellitus, rheumatoid arthritis, chronic kidney disease, obesity, and chronic obstructive
pulmonary disease [1–3].
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Periodontitis is predominantly a bacterial infection involving the accumulation of different
bacteria on the non-shedding surfaces. In susceptible patients, dental plaque comprises periodontal
pathogenic microorganisms which initiate and trigger a dysfunctional inflammatory immune response,
which results in the destruction of the underlying supporting tissues. The host response to the
initiating periodontopathogens is mostly a genetically determined non-modifiable risk factor. However,
modifiable or eliminative risk factors play an important role in changing the susceptibility or resistance
of individuals to the disease. Such risk factors are smoking, poorly controlled diabetes mellitus,
obesity, stress, osteopenia, and inadequate intake of calcium and vitamin D. [1]. The most important
modifiable local risk factor is poor oral hygiene, which may initiate the infective inflammatory process
in periodontal tissues.
Treatment of periodontitis involves a fine balance of various non-surgical and surgical methods
carried out in order to reduce periodontal pocket depth, access residual plaque, initiate the regeneration
of periodontal supporting tissues and decrease the risk of disease progression. Subgingival anti-
infective therapy performed together with self-performed plaque control provides significant benefits
in clinical parameters and improvement of systemic inflammatory markers [4].
Non-surgical periodontal treatment consists of professional removal of plaque and calculus,
elimination of plaque retentive factors, oral hygiene instruction, chemical plaque control and antibiotic
medication. Treatment of teeth with tooth/site-dependent factors (e.g., the presence of plaque,
anatomic features, deep pocket, furcation involvement, intrabony defect) is less predictable and
bears an elevated risk of the progression of the breakdown of periodontal tissues [5]. Mechanical
therapy alone may have limited effect on some periodontopathogens and fail to eliminate them
in ecological niches (e.g., infected epithelial and connective tissue pocket wall, scratches left after
mechanical debridement, resorption lacunae, accessory root canal, dentinal tubules, dorsal part of the
tongue, tonsils, oral mucosa, etc.). These limitations indicate the importance of the employment of
pharmacologic agents in periodontal therapy [4].
Pharmacologic therapies are based on the administration of antimicrobials (including antiseptics
and local delivery or systemic regimen of antibiotics) and probiotics and host modulation. Systemic
antimicrobials should be applied adjunctively to mechanical non-surgical treatment—preferably in
patients with aggressive or recurrent forms of periodontitis—and may provide additional benefits in
case of very deep pockets or specific microbial infections. Systemic antimicrobial therapy is the most
effective when the mechanical disruption of the subgingival biofilm is performed during subgingival
debridement. The combination of amoxicillin and metronidazole or ciprofloxacin and metronidazole
show greater clinical effectiveness than monotherapy [4,6].
The local delivery of antimicrobial drugs may reduce the systemic adverse effects and provide
effective drug concentrations in the periodontal pockets to eliminate the pathogens from the
subgingival area [7,8]. Local application of antibiotics has been advocated for patients with localized
lesions or a limited amount of non-responding or recurrent sites [4]. In the literature, many articles
are about the development of various types of delivery systems (fibers, films, gels, strips, injectable
systems, microparticles) containing different active agents (tetracycline, doxycycline, chlorhexidine,
clindamycin, metronidazole, amoxicillin, povidone-iodine) [7,9–22].
In the last 10–15 years, lipid drug delivery received considerable attention due to advancement
in the field. Administration of lipid materials is most prevalent in solubility enhancing, lymphatic
transport targeting, and/or intestinal transport modulation aiming the increased bioavailability of
drug formulations, but creating sustained release systems, covering the bitter or bad taste of active
ingredients or protecting drug molecules susceptible to different environmental factors may also be a
purpose for the application of lipid excipients [23].
In periodontal therapy, using lipid formulations may provide the prolonged liberation of
hydrophilic antimicrobial agents, while protecting them from decomposition in hydrophilic media
and masking their unpleasant taste.
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The aim of the recent study was to develop a lipid-based formulation, which can be inserted into
the periodontal pocket, has mucoadhesive features and provides sustained delivery of antimicrobial
agents, such as amoxicillin, metronidazole and zinc derivatives (zinc hyaluronate, and zinc gluconate).
Due to the fact that the applications site possesses special qualities, the following requirements were
considered to be met by our drug delivery system: to have a softening point at body temperature to
help the adaptation of the dosage form to the shape of periodontal pockets; to be biodegradable to let
the delivery system vanish slowly from periodontal pockets as healing commences; to be biocompatible
not to trigger further inflammatory processes; and to provide sustained drug release for at least one
week. In addition to softening, the purpose of the lipid composition was to create an anhydrous
medium, which could protect the antimicrobial agents (amoxicillin) from decomposition and can have
a taste-masking effect in the case of metronidazole. This paper also aims to investigate the properties
of these delivery systems. During the development, different investigational methods were employed
in order to examine the properties of the delivery systems. The measurements carried out included
differential scanning calorimetry (DSC), X-ray diffraction (XRD), and mucoadhesion measurements,
and also drug diffusion studies and antimicrobial effectiveness investigations.
2. Materials and Methods
2.1. Materials
Suppocire BP (SBP) pellets (Gattefossé Ltd., Saint-Priest, France), Methocel E4M HPMC (Colorcon
Ltd., Dartford, United Kingdom), Kolliphor RH40 (KP) (BASF ChemTrade GmbH, Ludwigshafen,
Germany), amoxicillin (AMX) (Antibióticos de León S.L.U., León, Spain), cetostearyl alcohol (CA),
metronidazole (MZ), zinc gluconate (ZnGlu) (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary),
and zinc hyaluronate (ZnHA) (Richter Gedeon Ltd., Budapest, Hungary) were used to create the
delivery systems.
For the mucoadhesion and drug dissolution tests, a phosphate-buffered saline (PBS) solution
was prepared by dissolving 8 g/dm3 NaCl, 0.2 g/dm3 KCl, 1.44 g/dm−3 Na2HPO4 · 2 H2O and
0.12 g/dm3 KH2PO4 (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary) in distilled water. The pH
was adjusted to 7.4 by adding an adequate amount of 0.1 M HCl. The mucin (porcine gastric mucin
type II, Sigma-Aldrich, Saint Louis, MO, USA) was used in the form of an 8 w/w% suspension.
2.2. Composition of the Drug Delivery Systems
The exact composition of different formulations can be found in Table 1. Five main components
were used to create the delivery systems. A lipophilic component SBP was chosen as lipid base and
CA was used as a structure-building component. All of the lipid components can be safely used on
mucosae, where the SBP can soften at body temperature providing the accommodation of the dosage
form to the periodontal pocket.
Table 1. Composition of formulations 1–6. All values are given in w/w%.
Formulation No. Component 1 2 3 4 5 6
Suppocire BP 33% 33% 33% 47% 46.8% 32%
Cetostearyl alcohol 40% 40% 40% 40% 40% 40%
Kolliphor RH40 10% 10% 10% 10% 10% 10%
Methocel E4M 2% 2% 2% - - -
Metronidazole - 15% 7.5% - - 15%
Zinc hyaluronate - - - 3% 3% 3%
Amoxicillin 15% - 7.5% - - -
Zinc gluconate - - - - 0.2% -
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Cetostearyl alcohol (CA) consists of mainly stearyl and cetyl alcohols; it is a mixture of solid
alcohols, it was used to increase the softening temperature of the formulations.
KP, a polyoxyethylene 40 castor oil derivative, was used as a surface-active agent, which helps
the wetting of the formulation in the periodontal pocket; thus, it promotes its swelling and erosion.
HPMC (hydroxypropyl methylcellulose) and ZnHA were applied as gelling and mucoadhesive
components. During the erosion of the formulations, they can help to prolong the retention time
of the systems in the periodontal pockets. HPMC is often used as a mucoadhesive agent in oral
formulations such as films [24] or buccal tablets [25] to increase the residence time of the delivery
system, while ZnHA is regularly applied in topical gels to accelerate the healing of wounds of different
etiologies and to decrease the chance of a possible bacterial superinfection [26], or may be used as a
mucoadhesive agent in ophthalmic solutions to lengthen clearance and provide higher efficiency [27].
AMX or MZ, which are regularly applied orally for PD treatment, were incorporated into the
vehicles. ZnGlu was also incorporated into one of the formulations as an antimicrobial agent. Zn salts
have a known antibacterial effect, which can be useful in periodontitis treatment.
All the formulations were created by a melting and homogenation method. At first, the two
lipophilic components (cetostearyl alcohol and Suppocire BP) and the surfactant (Kolliphor RH40) were
melted together at 70 ◦C on a hot plate (IKA-WERKE RCT B, ETS-D4, IKA Werke GmbH and Co. KG,
Staufen im Breisgau, Germany), then the polymer (zinc hyaluronate or Methocel E4M) was suspended
and homogenized with an overhead stirrer at 50 RPM (Digital Overhead Stirrer–DLH, VELP Scientifica,
Usmate Velate, Italy). The antimicrobial agent(s) (amoxicillin, metronidazole, zinc gluconate) was/were
dispersed and homogenized at 50 ◦C to avoid thermal decomposition [28]. Delivery systems were
created by molding the melted formulations into round shaped silicone molds. Cylindrical drug
delivery systems were 1.5 mm in thickness and 9 mm in diameter.
2.3. Differential Scanning Calorimetry (DSC) Measurements
The softening temperature and the melting point of the formulations were determined by
differential scanning calorimetry measurements with a Mettler-Toledo DSC 821e instrument in an
argon atmosphere (100 mL/min). The temperature was raised from +5 ◦C to +100 ◦C by 5 ◦C per
minute. Ten milligrams of the samples were put in 40 µL aluminum pans. The tops were holed,
then the pans were sealed.
2.4. X-ray Powder Diffraction (XRD) Analysis
Diffractograms of the raw materials (SBP, CA, KP, MZ, AMX, HPMC, ZnHA, ZnGlu) and the
formulations were obtained with a Bruker D8 Advance diffractometer (Bruker AXS GmbH, Billerica,
MA, USA) system with Cu K λI radiation (λ =1.5406 Å). Each sample was scanned at 40 kV and 40 mA
in the interval of 3◦–40◦ 2θ, at a scanning speed of 0.1/s and a step size of 0.010◦.
2.5. Mucoadhesion Measurements
Adhesion tests were performed with a TA-XT Plus (Texture analyzer, ENCO, Spinea, Italy)
instrument equipped with a 1 kg load cell and a cylinder probe with a diameter of 1.0 cm. Twenty
milligrams of the sample attached to the cylinder probe was placed in contact with a filter paper disc
impregnated with 50 µL mucin dispersion (8 w/w%, prepared in PBS (pH = 7.4)). A 2500 mN preload
was applied for 3 min (the compression speed was 2.5 mm min–1). The cylinder probe was then moved
upwards to separate the sample from the substrate at a prefixed speed of 2.5 mm min–1. Polymer
solutions, prepared by dissolving the solid polymers in PBS, were analyzed during the mucoadhesion
measurements where ZnHA and HPMC concentrations were 0.5, 1, 2, 5, and 10 w/w%. Ten parallel
measurements were performed.
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2.6. Investigation of the Swelling and Erosion of Formulations
A gravimetrical analysis was carried out in order to investigate the water absorption capacity of
the different formulations, and to examine the effects of the mucoadhesive polymers on the erosion
profile of the delivery systems. Prior to the measurements, the formulations were weighed with an
analytical scale and put in 10 mL of PBS solution thermostated at 37 ◦C for various time periods (0.5, 1,
2, 4, 6, 8, 24, 36, 48, 72, 96, and 168 h). Subsequent to the designated time period, the formulations were
weighed again, which was followed by drying at room temperature. After the formulations had totally
dried out, a third weight measurement was carried out. Evaluation of the changes in the mass of the
formulations could help the determination of the absorption capacity and the swelling related erosion
profiles. For each sampling time three parallels were applied.
2.7. Drug Dissolution Tests
The in vitro drug release profiles of formulation nos. 1, 2, 3, and 6 were determined.
The compositions were weighed with an analytical scale, put in 50-mm-long dialysis tubes
(Spectra/Por® Standard RC tubing, MWCO: 12-14 kD) and sealed with closures. The tubes containing
the formulations were placed in 7.5 mL of PBS solution thermostated at 37 ◦C. Drug release was
investigated for seven days and three parallel measurements were carried out. One milliliter of
samples was taken (at 0.5, 1, 2, 4, 6, 10, 24, 30, 48, 72, 96 and 168 h) and were replaced with 1 mL of PBS
solution. The active agents AMX and MZ were separated with an HPLC system (where necessary) and
quantified by a UV spectrophotometer attached to the HPLC at 230 nm.
The solution obtained was filtered through a 0.20 µm polyethersulfone syringe membrane filter
and injected directly into the HPLC system. The AMX and/or MZ content was quantified with a
Merck-Hitachi LaChrome Elite HPLC (Hitachi High Technologies America, Inc., Schaumburg, IL,
USA). AMX and MZ were measured on a Kinetex 250 mm × 4.6 mm column packed with 5 µm
EVO C18, 100 Å (Phenomenex Inc., Torrance, CA, USA). Elution was performed with 20:80 (v/v)
Methanol-NaH2PO4 (0.05 M) at a flow rate of 1 mL/min. Prior to the elution, the eluent was degassed
and filtered through a 0.45 µm pore-sized glass filter funnel. The run time was seven minutes. Detection
was performed via absorption at 230 ± 4 nm. 3 µL of sample were injected, and the elution was carried
out at a sample temperature of 25 ◦C and at a column temperature of 25 ◦C.
Quantitative determination was achieved by comparison with the spectra of standards. The stock
solutions of AMX and MZ (2 mg/mL) were prepared in PBS and stored at 4 ◦C. The stock solutions
were used within 24 h. Working standards (0.5, 1, 1.5, and 2 mg/mL) were prepared freshly by diluting
the stock solution with the mobile phase prior to the HPLC analysis. Calibration plots were freshly
prepared and were highly linear (R2 (AMX) = 0.9990 and R2 (MZ) = 0.9998). Limit of detection (LOD)
and limit of quantification (LOQ) of the quantitative determination was 3.308 and 10.020 µg/mL,
respectively, while in the case of amoxicillin and metronidazol, the resolution (RS) was 3.10.
Drug recovery tests were also performed, where the incorporated metronidazole was extracted
with water at the melting point of the lipid formulations. The results of the extracted drug amounts
corresponded to the incorporated drug amounts (99.50 ± 0.30%).
2.8. Microbiological Investigation
Microbiological study was conducted in order to measure the antibacterial effectiveness of the
developed formulations. Typical periodontopathogenic bacteria: Fusobacterium nucleatum (ATCC®
25586™), Parvimonas micra (ATCC® 33270™), Eikenella corrodens (ATCC® 23834™), Porphyromonas
gingivalis (ATCC® 33277™), Aggregatibacter actinomycetemcomitans (ATCC® 29524™), and Prevotella
intermedia (118710) control strains were used. A 1 McFarland standard concentration bacterial
suspension of each bacterial strain was made separately with 0.9% NaCl solution (in suspension
it is equivalent to approximately 3 × 108 colony forming units/mL). The suspension was spread
onto a horse blood agar plate, where then formulations were placed on. The concentration of the
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active agent(s) was 15 w/w%: 15 w/w% of AMX or MZ alone (formulations 1 and 2), or 7.5 w/w%
of both AMX and MZ (formulation 3). The delivery systems made with ZnHA contained 3 w/w%
ZnHA (formulation 4) or 3 w/w% ZnHA and 0.2 w/w% ZnGlu (formulation 5) or 3 w/w% ZnHA
and 15 w/w% MZ (formulation 6). After 24 h of incubation in anaerobic conditions, the diameter of
the inhibition zones was measured. The formulations were then put on a new horse blood agar plate,
also inoculated with 1 McFarland standard concentration freshly made bacterial suspension of each
of the above-mentioned bacterial strains. The plates were then put in an anaerobic chamber for 24 h.
This was repeated until no inhibition zone could be detected.
3. Results and Discussion
3.1. Differential Scanning Calorimetry (DSC) Measurements
DSC was used to determine the softening temperature and the melting point of the formulations.
The lipid base of the compositions was SBP, which is often used as a base for suppositories [29].
In our measurements, it has a melting point at 39.08 ◦C (Figure 1).
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Figure 1. DSC curves of pure components (Kolliphor RH40, Suppocire BP and Cetostearyl alcohol) and
formulations containing 15 w/w% of amoxicillin, 15 w/w% of metronidazole, 7.5 w/w% of amoxicillin
and metronidazole, 3 w/w% of zinc hyaluronate, 3 w/w% of zinc hyaluronate and 0.2 w/w% of zinc
gluconate, and 3 w/w% of zinc hyaluronate and 15 w/w% of metronidazole.
Cetostearyl alcohol is mostly used as a surfactant, a co-surfactant or as a viscosity increasing
agent in semisolid formulations. According to our DSC measurements, the melting point of the pure
component is at 61 ◦C (Figure 1.). In our earlier study [30], we presented that where CA remains
partially in a crystalline state; thus, sustained drug release could be achieved.
The esults of DSC measurements show that K lliph r RH40 has a congealing temperature
approximately betw en 20—30 ◦C (Figure 1), which corr sponds with the lit rature data [29].
No sharp peaks could be perceived on the curves belonging to the polymers (zinc hyaluronate
and Methocel E4M), and zinc gluconate in this temperature range (10—100 ◦C). Glass transition of
these components starts over 50 ◦C (Figure 1.)
Formulation nos. 1–6 were examined to investigate the possible modifying effect of the
incorporated drugs and excipients on melting point. Antibiotics or other suspended materials may
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partially dissolve in the lipid base, therefore, the effect of various incorporated components of different
amounts on the melting point was also investigated.
In all formulations, the sharp peaks of SBP and CA disappeared, even the two peaks of CA
morphed into one, and shifted to temperatures between the melting points of the two pure components.
At approximately 30 ◦C, a moderate melting can be observed, but total melting only occurs between
40 and 50 ◦C. A moderate melting starts at 30 ◦C, which supports the softening of the systems, but,
as there are components with melting points at about 50 ◦C, which suggests the presence of a coherent
structure at body temperature; thus, total melting of the formulations will not occur, and sustained
drug release may be possible.
The type of the drug did not influence the melting point greatly, but differences in the shape of
the curves are noteworthy. In the case of formulations containing zinc salts or amoxicillin, peaks at
approximately 50 ◦C (probably the two fused peaks of CA) broadened, meaning an earlier onset of
melting, while metronidazole containing ones show sharper peaks.
By the thorough analysis of the DSC results, we could conclude that no peaks of any curve
belonging to different formulations could be associated with the decomposition of any component,
thus, the constituents are expected to be stable in this temperature range.
3.2. XRD Analysis
Active ingredients were suspended in the melted lipids. XRD analyses were carried out to
investigate their final state (suspended or dissolved). The presence of solid crystals is indicated by
sharp peaks in the diffractograms, while dissolved components, as they do not possess a crystalline
structure, are not detectable. The amorphous structure is often a substantial feature of polymers; thus,
the crystalline structure and its characteristic peaks are absent from the diffractograms.
All of the components, except for HPMC, Kolliphor RH40, zinc hyaluronate, and zinc gluconate,
have a crystalline structure according to the XRD diffractograms presented in Figure 2.
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amoxicillin, metronidazole, zinc hyaluronate, zinc gluconate, Methocel E4M) and formulations
containing 15 w/w% of amoxicillin, 15 w/w% of metronidazole, 7.5 w/w% of both of amoxicillin
and metronidazole, 3 w/w% of zinc hyaluronate, 3 w/w% of zinc hyaluronate and 0.2 w/w% of zinc
gluconate, and 3 w/w% of zinc hyaluronate and 15 w/w% of metronidazole.
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SBP and CA have similar molecular structures, which will result in analogous diffractograms.
This means that in the diffractograms of the formulations containing all of the components, it is hard
to differentiate between the two lipid components. The more intensive peak of CA could overlap with
and cover the peak of SBP at the same 2θ value in the preparations. This peak, which belongs to CA,
has decreased in intensity in the diffractograms of the formulations, which implies that the crystallinity
of CA has decreased, which is in accordance with the DSC results, where the two peaks of pure CA
have fused together and shifted to a lower temperature range.
A characteristic peak linked to SBP at the 2θ value of approximately 5◦ is present in all
formulations with varied intensity, also indicating the crystalline structure of the lipid base.
The characteristic peaks of AMX and MZ could be separated from those of the lipid components.
The presence of characteristic peaks in the diffractograms is the sign of solid particles in the
formulations. AMX and MZ have a characteristic peak at the 2θ value of 18.1◦ and 12.3◦, respectively.
Peaks at the mentioned 2θ values could be observed in the diffractograms of formulations containing
AMX or MZ.
The presence of ZnHA or ZnGlu in the preparations could not be demonstrated by this experiment
because of their amorphous structure to which no characteristic peak belongs in an XRD diffractogram.
The partially crystalline form of the lipid matrix (CA and SBP) could contribute to the coherent
structure of the system, which does not melt at body temperature, thus providing sustained release of
antibiotic compounds, while the suspended form of the drugs and antimicrobial agents may provide
a more stable form, therefore protecting the drugs from the negative effects of the environment and
decomposition as well.
3.3. Investigation of the Mucoadhesive Properties of the Applied Polymers
Subsequent to insertion into the periodontal pocket and wetting of the lipid system,
the mucoadhesive polymers at the interface of the lipid and the periodontal fluid get hydrated,
swell, and form a gel layer, providing adhesion to the application site.
The mucoadhesive properties of the polymers were investigated by means of a tensile test,
which is an in vivo-like mucoadhesion method because it mimics the adhesion to a biological surface.
Adhesive force and work were determined on the basis of the force-distance curve obtained during the
tensile test (Table 2). In this measurement, a larger concentration range of polymers was investigated.
The larger concentration range of polymer solutions could mimic the gel layer formed at the surface of
the lipid formulation; therefore, the mucoadhesion properties of the delivery system.
Table 2. Adhesive force and work of the gels at different polymer concentrations. Mean values and SD,
n = 10. (ZnHA = Zinc hyaluronate; HPMC = Methocel E4M, hydroxypropyl methylcellulose).
Polymer Polymer Conc. (%)
Adhesive Force (mN) Adhesive Work (mN.mm)
Mean± SD Mean± SD
ZnHA
0.5 1579.0 71.1 167.3 9.9
1 1786.8 230.9 202.9 37.6
2 1789.6 98.9 207.1 19.6
5 2299.5 111.2 397.9 30.8
10 2514.4 69.6 1166.6 163.9
HPMC
0.5 73.5 28.3 16.2 6.3
1 145.6 62.3 28.7 17.8
2 325.7 137.1 60.7 16.1
5 607.8 358.7 180.7 64.5
10 779.4 265.5 527.1 170.0
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In our measurements, in both cases, the adhesive force and work continuously increased
with increasing polymer concentrations; ZnHA showed remarkable adhesion over the whole
investigated polymer concentration range, indicating better mucoadhesion to the model surface;
thus, ZnHA may provide a better mucoadhesive feature for the lipid formulations than HPMC, and the
multipotent (adhesive and antimicrobial) characteristics of the former excipient can be beneficial in
periodontal therapy.
3.4. Swelling and Erosion Profiles of Delivery Systems
In addition to melting and softening, swelling and erosion of the lipid formulation can also affect
drug release. In this case, the swelling of the polymer can result in a gel layer on the surface of the
delivery system, and then this layer can be slowly removed thanks to the elimination mechanisms
in the oral cavity and periodontal pocket. In addition to this mechanism, the melted lipid and the
surfactant can also be eliminated from the formulation by emulsification with the produced oral
biological medium, the gingival crevicular fluid.
In our experiments the swelling ratio (%) was calculated as follows [31]:
Swelling ratio (%) = ms / mo × 100% (1)
where ms is the mass of the formulations after immersed in water for the specified time and mo is the
mass of the original formulations (prior to the immersion into water).
During the measurements, delivery systems were immersed into purified water to investigate the
swelling and erosion properties of the different preparations, because different antimicrobial agents
and mucoadhesive polymers are incorporated into the systems. The swelling ratio of the different
compositions can be observed in Figure 3a,b, while the erosion profiles are shown in Figure 4a,b.
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Based on the swelling profile, two groups can be distinguished. Swelling ratio of formulations
containing ZnHA and/or a higher amount of MZ shows a higher water absorption capacity than
formulations with AMX or lower concentrations of MZ and HPMC as polymer; the former group had a
maximum swelling ratio of approximately 560%, while the latter group was only approximately 300%.
This phenomenon may be driven by the different swelling and solubility of components: i) ZnHA
is a material possessing a strong water absorption capacity, and ii) MZ owns a sparingly water-soluble
feature but better than amoxicillin. Because of the higher water absorption-capacity of ZnHA and
better solubility of MZ, water could access the lipid structure with ease resulting in higher swelling of
formulations; ZnHA may bind a very large amount of water and break the coherent lipid structure,
and through the generated superficial microgaps more ZnHA particles become accessible to water,
thus binding more medium. MZ may work in a highly similar way, but in this case the applied
polymer (HPMC) binds the water. The better solubility of MZ compared to AMX, also contributes to
quicker dissolution from the systems, and the dissolved MZ (leaving capillaries in the structure) may
provide water with a trouble-free entry accessing polymer particles incorporated into the delivery
systems. The more drug is dissolved from the preparations, the more capillaries are made, and through
more capillaries, more polymer particles may be accessed, which results in a higher water binding.
When ZnHA and a high concentration of MZ (15 w/w%) are applied together, no extra swelling can be
observed. This phenomenon can be explained by the structure of the formulations, the swelling power
of the polymers may not be vigorous enough to destroy the coherent solid structure of the delivery
system; thus, combining the two components (MZ and ZnHA) did not result in over-swelling.
AMX and lower concentrations of MZ are not capable of generating the same effect due to the
creation of fewer capillaries because of the poorer solubility of amoxicillin compared to MZ and the
lower concentration of MZ; therefore, the swelling of those systems remains below the level provided
by the formulations having ZnHA or more MZ incorporated into them.
Accordingly, the swelling profiles of the different formulations may be dependent on the
incorporated materials, their attributes and the strength of the coherent lipid structure.
Erosion ratio (%) was calculated from the following equation [30]:
Erosion ratio (%) = mo−md/mo × 100% (2)
where mo is the mass of the original formulations and md is the mass of the dried formulation after the
swelling and erosion measurements.
In contrast with the results of the swelling measurements, the erosion of different compositions
are not highly different from each other (Figure 4a,b). The weight of all formulations has decreased
to approximately 60% of that of the original ones. Two main mechanisms may control the erosion
of the drug delivery systems. One is the emulsification of components melted at body temperature
(37 ◦C) with water. The other is the swelling power of incorporated polymers, destroying the coherent
structure, and the erosion of the gel layer formed at the surface. The similarities in the erosion
profiles can highlight that the destruction of delivery systems may be more likely to be defined by
the emulsification of the melted lipid components, as the lipid composition and ratio and, therefore,
the basic structure of the different compositions, are almost the same. The swelling experiments also
suggest the same findings, because the strength of the coherent structure could limit the swelling
of polymers.
3.5. Investigation of Drug Release from Formulations
Drug dissolution measurements were carried out in order to evaluate the drug release profiles of
the prepared formulations which contain MZ. An HPLC method was used to quantify the dissolved
drug from the preparations.
The amount of released MZ from formulations containing the antibiotic drug is shown in Figure 5.
Preparations containing 15 w/w% MZ and HPMC or ZnHA have shown similar drug release profiles.
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A plateau phase commencing at approximately at the 100th hour is indicated in both cases, which is in
accordance with a total drug release.Pharmaceutics 2019, 11, x FOR PEER REVIEW 11 of 18 
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amoxicillin and 7.5 w/w% metronidazole).
However, the drug release curves of formulations containing 7.5 w/w% MZ indicates that only
one-third of the amount was liberated from the preparations despite the fact that half of the amount
had been incorporated into the compositions.
The drug release mechanism can be characterized with the following exponential equation:
Mt/ ∞ = k tn (3)
where Mt/M∞ is the fraction of drug released, k is the kinetic constant and n is the release exponent
describing the mechanism of the release.
On the basis of literature data, in case of swelling controlled cylindric drug delivery systems,
if the release exponent is 0.45, the dug release mechanism is a Fickian diffusion, while the release
exponent is between 0.45 and 0.89, the release corresponds to anomalous (non-Fickian) diffusion [32].
In our case, the highly swellable formulations (Formulations 2 and 6) showed non-Fickian diffusion,
which indicates that Fickian diffusion coupled with the swelling of the incorporated polymer. In the
formulation where swelling is moderated (Formulation 3) alone Fickian diffusion characterizes the
drug release (n = 0.4567) (Table 3).
Table 3. Release exponent (n), kinetic constant (k) and R2 values of curves fitted on the drug release
curves of formulations 2, 3, and 6.
Formulation No. n k R2
2 . 1555 0.9802
3 0.4567 995.6 0.9926
6 0.6671 1360.6 0.9880
The phenomenon detailed above in Section 3.4. may be in the backgroun of such results. MZ,
which is a more soluble material in water compared to AMX, could be liberated more quickly from
formulations cr ating capillaries, which contribute to a higher swelling and therefore allow water to
access all th suspende drug in the delivery systems. On the contrary, wh n smaller amounts of MZ
Pharmaceutics 2019, 11, 142 12 of 19
are incorporated into the delivery systems with AMX—a substance with lower water solubility—fewer
capillaries may be formed during drug release, permitting less water to penetrate the systems and
resulting in non-complete drug dissolution.
The application of ZnHA did not change the release profile, which can be explained by the similar
swelling and erosion profiles of the formulation containing 15 w/w% MZ with and without ZnHA.
Summarizing the results of drug dissolution testing, a sustained release of drugs could be achieved
with these compositions, and the main factors affecting drug release are swelling (driven by the applied
hydrophilic components such as polymer, active ingredients and their concentration) and the strength
of the coherent lipid structure.
3.6. Microbiological Investigation
Numerous different species of microorganisms may be present in the oral cavity or on the dental
surfaces. The composition of the oral microbiota varies widely from person to person, from place to
place and naturally with dietary habits [33,34].
Many journal articles aim to define the species of bacteria which have a contribution to the
initiation and progression of periodontal disease [33–41], but the high number of different strains
and cultivation difficulties make it almost impossible. Moreover, only a small percentage of the
subgingival oral microbiota has a role in disease pathogenesis [42,43]. Pathogen organisms which
could be linked to and may have correspondence to the disease are the following: Porphyromonas
gingivalis, Prevotella intermedia, Bacteroides forsythus, Actinobacillus actinomycetemcomitans, Treponema
denticola, Tannerella forsythia, Fusobacterium nucleatum, Fusobacterium periodonticum, Prevotella intermedia,
Prevotella nigrescens, Parvimonas micra, Campylobacter gracilis, Campylobacter rectus, Campylobacter showae,
Eubacterium nodatum, Streptococcus constellatus, Eikenella corrodens, Streptococcus spp., etc. [33,42–45].
According to Kolenbrander et. al. [45], these species can be separated into two categories concerning
plaque formation. Species in the first category—initial colonizers—are thought to stick to the tooth
surface and proliferate. The second group—late colonizers—binds to the first group of bacteria via
different interactions.
In our formulations, AMX or MZ was incorporated in 15 w/w% concentration, and a system
containing 7.5/7.5 w/w% AMX and MZ was also compiled. In addition to these formulations, ZnHA,
ZnHA and ZnGlu, and ZnHA and MZ containing ones were also created and investigated.
AMX, which is a semi-synthetic penicillin derivative, is known to be effective against many
aerobic or anaerobic Gram-positive and Gram-negative bacteria [13,46].
MZ is an antibacterial agent, included in the nitroimidazole group. Numerous bacteria and
protozoa—even anaerobes—are known to be susceptible to MZ [7,47].
In periodontal disease therapy, MZ and AMX may be used as an adjunct to scaling and root
planning therapies locally or systematically [48–50].
Hyaluronic acid is a naturally occurring polysaccharide of the extracellular matrix of connective
tissue, synovial fluid, and soft periodontal tissues as well. Its application in the treatment of the
inflammatory process is established in different medical areas such as orthopedics, dermatology,
and ophthalmology. In the treatment of periodontal diseases, hyaluronic acid shows anti-inflammatory
and anti-bacterial effects [51].
Zinc salts may have a beneficial effect when used in mouth rinses, can possibly decrease plaque
formation by inhibiting glycolytic enzymes and may prevent the attachment of bacteria to the tooth
surface [52]. These salts administered in combination with other antimicrobial agents may show a
synergism by means of antibacterial effect [53].
In view of the beneficial properties of hyaluronates, zinc hyaluronan was chosen as a combined
mucoadhesive and antimicrobial agent for our other set of formulations.
The antibacterial effectiveness of samples with Zinc hyaluronate was also measured to determine
if the polymer has an antibiotic effect alone or in combination with other molecules like zinc gluconate
or metronidazole.
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In our microbiological investigation, where the antimicrobial activity of our formulations was
measured, we used six different strains of oral pathogen bacteria, which may contribute to the initiation
of periodontitis. These were the following: Eikenella corrodens, Prevotella intermedia, Parvimonas micra,
Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis.
Eikenella corrodens—a facultative anaerobic, Gram-negative bacterium—is a human (mostly
oral) pathogen. E. corrodens appears to be susceptible to beta-lactam antibiotics, but resistant to
metronidazole [54].
Parvimonas micra (also known as Peptostreptococcus micros or Micromonas micros)—an anaerobic,
Gram-positive coccus—is the member of the normal human gastrointestinal flora [55]. According
to Rams et al., it shows high susceptibility to penicillin but metronidazole seems to be less effective
against the bacterium [56].
Prevotella intermedia—a Gram-negative anaerobic bacterium with black pigments—is often
connected with oral and subgingival diseases. P. intermedia shows susceptibility to penicillin and
metronidazole [57].
Fusobacterium nucleatum—a mostly oral and periodontal anaerobic pathogen—can be linked to a
variety of human diseases. Strains isolated from endodontic infections seem to be highly sensitive to
amoxicillin and a little less susceptible to metronidazole [58,59].
Aggregatibacter actinomycetemcomitans—a Gram-negative, facultatively anaerobic rod—is
frequently associated with most forms of periodontitis and numerous oral infections. Amoxicillin is
effective against the bacterium, while it shows much less susceptibility to metronidazole [60,61].
Porphyromonas gingivalis—an obligately anaerobic, Gram-negative black-pigmented rod—is the
most commonly linked microorganism to periodontal disease. According to susceptibility tests,
P. gingivalis is sensitive to amoxicillin and metronidazole [62,63].
Agar plates were 90.0 mm in diameter, thus, the largest possibly detectable inhibition zone could
be around 90.0 mm.
The results of the microbiological investigations can be found in Figure 6.
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The largest measurable inhibition zone wa 74.0 mm in diameter and was because of an amoxicillin
containing formulation an agar plate i oculated with Eikenella corrodens after the first 24 h.
According to our measurements, Parvimonas micra was the most sensitive microorganism to AMX
containing formulations as the compositions could provide 17 days of effective drug release, while the
least susceptible pathogen was Eik n lla corrodens with only eight days of growth inhibition.
MZ susceptibility was slightly lower, as the effect against the m st sensitive bacterium
(Porphyromonas gingivalis) was only nine days. Eikenella corrodens was the least susceptible to MZ
as on the first 2 days no growth could be detected, but after two days bacteria were growing all over
the agar plate, and there was no inhibition zone arou d the formulation. This result is in accordance
with the literature data, where it was established that Eikenella corrodens is resistant to MZ [46].
Compositions containing 7.5 w/w% of AMX and MZ did not provide larger inhibition zones than
formulations containing only one antimicrobial agent as the antimicrobial effect lasted for shorter time
periods. P. gingivalis was an excep : this bacterial stra n was the only one with higher susceptibility
to the combination of the two antimicrobial drugs. In most cases, the growth inhibition effect of
combinations lasted longer than that of metronidazole. This could have been possible due to the
more potent antimicrobial effect of AMX. Lower susceptibility to the combination of AMX and MZ
compared t only AMX containing formulations may be due to the decreased concentration of AMX in
the combination containing compositions and the lower susceptibility of bacteria to MZ.
Whereas MZ is less potent against Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum,
and Parvimonas micra [56,58–61], with our formulations the growth inhibition effect can be provided
for up to 3 day .
Susceptibility to ZnHA is different among various bacterial strains. Aggregatibacter
actinomycetemcomitans and Eikenella corrodens show resistance to ZnHA, but combined with ZnGlu,
a longer effect can be observed in case of Aggregatibacter actinomycetemcomitans. Eikenella corrodens remains
unsusceptible to the combination of ZnHA and ZnGlu.
According to the results, the same susceptibility characterizes Porphyromonas gingivalis and
Prevotella intermedia when using ZnHA alone or in combination with ZnGlu.
In case of Parvimonas micra and Fusobacterium nucleatum, the results show that higher efficiency
may be achieved by administering a combination of ZnHA and ZnGlu instead of using only ZnHA.
The results imply that the combination of MZ and ZnHA provides a synergistic effect:
formulations containing both ZnHA and MZ provided longer growth inhibition against the
microorganisms than the active agents alone. The synergistic effect is most conspicuous against Eikenella
corrodens where formulations with MZ only lasted for two days, and ZnHA had no antibacterial effect
against the bacteria, while the combination showed a nine-day effect.
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All in all, the outcome of the antimicrobial investigation of ZnHA supports that alone it may not
be effective enough, but a combination with an antimicrobial drug (e.g., MZ) may provide a synergistic
and—in this case—a longer positive effect.
While the in vitro dissolution of AMX could not be detected, because the antibiotic had
decomposed thanks to the test environment (aqueous medium at 37 ◦C), the results of the
microbiological investigation imply that AMX stays stable when incorporated into the lipid
preparations, as it may provide 18 days of growth inhibition. (In this experiment, anaerobic
environment was provided, and the agar plates were changed day-by-day, which enabled amoxicillin
to remain stable in the aqueous agar medium.) This finding and the swelling experiments suggest that
the combination of AMX and a highly hydrophilic polymer with strong water binding capacity may
not be beneficial, because the sustained release of AMX could easily result in the decomposition of the
drug, even in the formulation prior to its dissolution.
4. Conclusions
An anhydrous lipid-based drug delivery system for the treatment of periodontitis was successfully
prepared and investigated. Possible administration and positive effect during disease treatment were
confirmed by the results of different measurements.
According to the DSC measurements, the melting of formulations starts at body temperature,
but total melting only occurs over 40 ◦C, which allows the presence of a coherent structure and
provides sustained drug release.
X-ray diffraction analysis indicates that the antibiotics are in a suspended form in the compositions,
and lipid components have a crystalline structure, which may also contribute to a prolonged drug
release and antimicrobial effect.
Thanks to the complex composition, our lipid formulations are swellable and degradable systems.
On the basis of our results, their swelling can be driven by the applied hydrophilic components
(polymer, active ingredients), their concentration and the strength of the coherent lipid structure,
while their erosion may be controlled mainly by the emulsification of the melted lipid components.
In formulations, where swelling is remarkable, Fickian diffusion is coupled with the swelling
of the incorporated polymer. Because of this phenomenon, which is indicated in the shape of the
diffusion curves, an anomalous (non-Fickian) diffusion model could be fitted to the diffusion curves.
The results of drug release and antimicrobial investigations show that with AMX incorporated into the
delivery systems, long drug diffusion can be obtained with a high antimicrobial effect. AMX can be
protected against degradation in hydrophilic circumstances at the periodontal pocket by using these
lipid formulations, which is suggested by our antimicrobial investigations. The sustained drug release
of MZ can also be provided, which may enable taste-masking and direct application of MZ in the
oral cavity without decreasing patient compliance. The combination of ZnHA and MZ improved the
antimicrobial characteristics of formulations compared to formulations containing only ZnHA or MZ.
These findings suggest that—when administered together—the two compounds have a synergistic
effect and might be a good alternative for patients allergic to penicillin and their derivatives.
In order to improve the residence time of melted lipid formulations in the periodontal pocket,
mucoadhesive polymers were applied. In our experiments, ZnHA had better adhesivity compared
to HPMC, and, additionally, it has a potential antibiotic feature. Nevertheless, the application of a
highly hydrophilic polymer with a strong water absorption capacity is questionable when the drug,
e.g., AMX, is not stable in aqueous circumstances.
The developed and evaluated lipid formulations containing antimicrobials may offer a solution to
such problems of local periodontal therapy as long-lasting effect. Moreover, the combination of MZ
and ZnHA can provide an effective antimicrobial therapy for penicillin-allergic patients.
Author Contributions: Investigation: A.L., E.U., and A.G.; writing—original draft: A.L. and M.B.-S.;
writing—review and editing: P.V., S.B., A.K., and E.C.
Pharmaceutics 2019, 11, 142 16 of 19
Funding: This research received no external funding.
Acknowledgments: We would like to express our gratitude to Azelis Hungary Ltd. and BASF Hungary Ltd. for
providing us with Suppocire BP pellets and Kolliphor RH40.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Genco, R.J.; Borgnakke, W.S. Risk factors for periodontal disease. Periodontology 2000 2013, 62, 59–94.
[CrossRef] [PubMed]
2. Tonetti, M.S.; Jepsen, S.; Jin, L.; Otomo-Corgel, J. Impact of the global burden of periodontal diseases on
health, nutrition and wellbeing of mankind: A call for global action. J. Clin. Periodontol. 2017, 44, 456–462.
[CrossRef]
3. Chapple, I.L.C. Time to take periodontitis seriously. BMJ 2014, 348, g2645. [CrossRef]
4. Graziani, F.; Karapetsa, D.; Alonso, B.; Herrera, D. Nonsurgical and surgical treatment of periodontitis:
How many options for one disease? Periodontology 2000 2017, 75, 152–188. [CrossRef]
5. Tomasi, C.; Koutouzis, T.; Wennström, J.L. Locally Delivered Doxycycline as an Adjunct to Mechanical
Debridement at Retreatment of Periodontal Pockets. J. Periodontol. 2008, 79, 431–439. [CrossRef] [PubMed]
6. Sanz, M.; Teughels, W. Innovations in non-surgical periodontal therapy: Consensus Report of the Sixth
European Workshop on Periodontology. J. Clin. Periodontol. 2008, 35, 3–7. [CrossRef]
7. Schwach-Abdellaoui, K. Local delivery of antimicrobial agents for the treatment of periodontal diseases.
Eur. J. Pharm. Biopharm. 2000, 50, 83–99. [CrossRef]
8. Bollen, C.M.L.; Quirynen, M. Microbiological Response to Mechanical Treatment in Combination with
Adjunctive Therapy. A Review of the Literature. J. Periodontol. 1996, 67, 1143–1158. [CrossRef]
9. Do, M.P.; Neut, C.; Metz, H.; Delcourt, E.; Mäder, K.; Siepmann, J.; Siepmann, F. In-situ forming composite
implants for periodontitis treatment: How the formulation determines system performance. Int. J. Pharm.
2015, 486, 38–51. [CrossRef]
10. Agarwal, R.K.; Robinson, D.H.; Maze, G.I.; Reinhardt, R.A. Development and characterization of
tetracycline-poly(lactide/glycolide) films for the treatment of periodontitis. J. Control. Release 1993, 23,
137–146. [CrossRef]
11. Sundararaj, S.C.; Thomas, M.V.; Dziubla, T.D.; Puleo, D.A. Bioerodible system for sequential release of
multiple drugs. Acta Biomater. 2014, 10, 115–125. [CrossRef] [PubMed]
12. Bromberg, L.E.; Braman, V.M.; Rothstein, D.M.; Spacciapoli, P.; O’Connor, S.M.; Nelson, E.J.; Buxton, D.K.;
Tonetti, M.S.; Friden, P.M. Sustained release of silver from periodontal wafers for treatment of periodontitis.
J. Control. Release 2000, 68, 63–72. [CrossRef]
13. Jain, N.; Jain, G.K.; Javed, S.; Iqbal, Z.; Talegaonkar, S.; Ahmad, F.J.; Khar, R.K. Recent approaches for the
treatment of periodontitis. Drug Discov. Today 2008, 13, 932–943. [CrossRef]
14. Al-Saeed, M.Y.; Babay, N. The use of povidone–iodine and hydrogen peroxide mixture as an adjunct to
non-surgical treatment of slight to moderate chronic periodontitis. Saudi Dent. J. 2009, 21, 127–133. [CrossRef]
15. Do, M.P.; Neut, C.; Metz, H.; Delcourt, E.; Siepmann, J.; Mäder, K.; Siepmann, F. Mechanistic analysis of
PLGA/HPMC-based in-situ forming implants for periodontitis treatment. Eur. J. Pharm. Biopharm. 2015, 94,
273–283. [CrossRef]
16. Tyagi, P.; Vaish, S.; Dodwad, V. Clinical efficacy of subgingivally delivered 0.5% controlled release
azithromycin gel in the management of chronic periodontitis. Indian J. Med. Sci. 2011, 65, 223–230.
17. Do, M.P.; Neut, C.; Delcourt, E.; Seixas Certo, T.; Siepmann, J.; Siepmann, F. In situ forming implants for
periodontitis treatment with improved adhesive properties. Eur. J. Pharm. Biopharm. 2014, 88, 342–350.
[CrossRef] [PubMed]
18. Kopytynska-Kasperczyk, A.; Dobrzynski, P.; Pastusiak, M.; Jarzabek, B.; Prochwicz, W. Local delivery system
of doxycycline hyclate based on -caprolactone copolymers for periodontitis treatment. Int. J. Pharm. 2015,
491, 335–344. [CrossRef] [PubMed]
19. Chinta, D.P.; Katakam, P.; Murthy, V.S.N.; Newton, M.J. Formulation and in-vitro evaluation of moxifloxacin
loaded crosslinked chitosan films for the treatment of periodontitis. J. Pharm. Res. 2013, 7, 483–490. [CrossRef]
Pharmaceutics 2019, 11, 142 17 of 19
20. Mayol, L.; Quaglia, F.; Borzacchiello, A.; Ambrosio, L.; Rotonda, M.I. La A novel poloxamers/hyaluronic
acid in situ forming hydrogel for drug delivery: Rheological, mucoadhesive and in vitro release properties.
Eur. J. Pharm. Biopharm. 2008, 70, 199–206. [CrossRef]
21. Lee, B.-S.; Lee, C.-C.; Lin, H.-P.; Shih, W.-A.; Hsieh, W.-L.; Lai, C.-H.; Takeuchi, Y.; Chen, Y.-W. A functional
chitosan membrane with grafted epigallocatechin-3-gallate and lovastatin enhances periodontal tissue
regeneration in dogs. Carbohydr. Polym. 2016, 151, 790–802. [CrossRef] [PubMed]
22. Sundararaj, S.C.; Thomas, M.V.; Peyyala, R.; Dziubla, T.D.; Puleo, D.A. Design of a multiple drug delivery
system directed at periodontitis. Biomaterials 2013, 34, 8835–8842. [CrossRef] [PubMed]
23. Jannin, V.; Musakhanian, J.; Marchaud, D. Approaches for the development of solid and semi-solid
lipid-based formulations. Adv. Drug Deliv. Rev. 2008, 60, 734–746. [CrossRef]
24. Perioli, L.; Ambrogi, V.; Angelici, F.; Ricci, M.; Giovagnoli, S.; Capuccella, M.; Rossi, C. Development of
mucoadhesive patches for buccal administration of ibuprofen. J. Control. Release 2004, 99, 73–82. [CrossRef]
25. Ramesha Chary, R.B.; Vani, G.; Rao, Y.M. In Vitro and In Vivo Adhesion Testing of Mucoadhesive Drug
Delivery Systems. Drug Dev. Ind. Pharm. 1999, 25, 685–690. [CrossRef] [PubMed]
26. Juhász, I.; Zoltán, P.; Erdei, I. Treatment of partial thickness burns with Zn-hyaluronan: Lessons of a clinical
pilot study. Ann. Burns Fire Disasters 2012, 25, 82–85.
27. Horvát, G.; Budai-Szucs, M.; Berkó, S.; Szabó-Révész, P.; Soós, J.; Facskó, A.; Maroda, M.; Mori, M.;
Sandri, G.; Bonferoni, M.C.; et al. Comparative study of nanosized cross-linked sodium-, linear sodium- and
zinc-hyaluronate as potential ocular mucoadhesive drug delivery systems. Int. J. Pharm. 2015, 494, 321–328.
[CrossRef]
28. Svahn, O.; Björklund, E. Thermal stability assessment of antibiotics in moderate temperature and subcritical
water using a pressurized dynamic flow-through system. Int. J. Innov. Appl. Stud. 2015, 11, 2028–9324.
29. Rowe, R.C.; Sheskey, P.J.; Owen, S.C. Handbook of Pharmaceutical Excipients, 6th ed.; Pharmaceutical Press:
London, UK, 2009; ISBN 978-0-85369-792-3.
30. Leber, A.; Budai-Szucs, M.; Urban, E.; Valyi, P.; Kovacs, A.; Berko, S.; Csanyi, E. Formulation and Investigation
of a Lipid Based Delivery System Containing Antimicrobials for the Treatment of Periodontal Disease. Curr.
Drug Deliv. 2018, 15, 887–897. [CrossRef] [PubMed]
31. Horvát, G.; Gyarmati, B.; Berkó, S.; Szabó-Révész, P.; Szilágyi, B.Á.; Szilágyi, A.; Soós, J.; Sandri, G.;
Bonferoni, M.C.; Rossi, S.; et al. Thiolated poly(aspartic acid) as potential in situ gelling, ocular mucoadhesive
drug delivery system. Eur. J. Pharm. Sci. 2015, 67, 1–11. [CrossRef]
32. Ritger, P.L.; Peppas, N.A. A simple equation for description of solute release II. Fickian and anomalous
release from swellable devices. J. Control. Release 1987, 5, 37–42. [CrossRef]
33. Moore, W.E.C.; Moore, L.V.H. The bacteria of periodontal diseases. Periodontology 2000 1994, 5, 66–77.
[CrossRef]
34. Costalonga, M.; Herzberg, M.C. The oral microbiome and the immunobiology of periodontal disease and
caries. Immunol. Lett. 2014, 162, 22–38. [CrossRef] [PubMed]
35. Darby, I.; Curtis, M. Microbiology of periodontal disease in children and young adults. Periodontology 2000
2001, 26, 33–53. [CrossRef]
36. Tsai, C.-Y.; Tang, C.Y.; Tan, T.-S.; Chen, K.-H.; Liao, K.-H.; Liou, M.-L. Subgingival microbiota in individuals
with severe chronic periodontitis. J. Microbiol. Immunol. Infect. 2018, 51, 226–234. [CrossRef]
37. Wang, J.; Qi, J.; Zhao, H.; He, S.; Zhang, Y.; Wei, S.; Zhao, F. Metagenomic sequencing reveals microbiota and
its functional potential associated with periodontal disease. Sci. Rep. 2013, 3, 1843. [CrossRef]
38. Laksmana, T. Metagenomic Analysis of Subgingival Microbiota Following Non-Surgical Periodontal Therapy:
A Pilot Study. Open Dent. J. 2012, 6, 255–261. [CrossRef]
39. Chen, H.; Liu, Y.; Zhang, M.; Wang, G.; Qi, Z.; Bridgewater, L.; Zhao, L.; Tang, Z.; Pang, X. A Filifactor
alocis-centered co-occurrence group associates with periodontitis across different oral habitats. Sci. Rep.
2015, 5, 9053. [CrossRef]
40. Liu, B.; Faller, L.L.; Klitgord, N.; Mazumdar, V.; Ghodsi, M.; Sommer, D.D.; Gibbons, T.R.; Treangen, T.J.;
Chang, Y.-C.; Li, S.; et al. Deep Sequencing of the Oral Microbiome Reveals Signatures of Periodontal Disease.
PLoS ONE 2012, 7, e37919. [CrossRef]
41. Könönen, E.; Müller, H.-P. Microbiology of aggressive periodontitis. Periodontology 2000 2014, 65, 46–78.
[CrossRef]
Pharmaceutics 2019, 11, 142 18 of 19
42. Kumar, P.S.; Griffen, A.L.; Moeschberger, M.L.; Leys, E.J. Identification of Candidate Periodontal Pathogens
and Beneficial Species by Quantitative 16S Clonal Analysis. J. Clin. Microbiol. 2005, 43, 3944–3955. [CrossRef]
[PubMed]
43. Teles, R.; Teles, F.; Frias-Lopez, J.; Paster, B.; Haffajee, A. Lessons learned and unlearned in periodontal
microbiology. Periodontology 2000 2013, 62, 95–162. [CrossRef]
44. Sanz, M.; Beighton, D.; Curtis, M.A.; Cury, J.A.; Dige, I.; Dommisch, H.; Ellwood, R.; Giacaman, R.;
Herrera, D.; Herzberg, M.C.; et al. Role of microbial biofilms in the maintenance of oral health and in
the development of dental caries and periodontal diseases. Consensus report of group 1 of the Joint
EFP/ORCA workshop on the boundaries between caries and periodontal disease. J. Clin. Periodontol. 2017,
44, S5–S11. [CrossRef]
45. Kolenbrander, P.E.; Palmer, R.J.; Periasamy, S.; Jakubovics, N.S. Oral multispecies biofilm development and
the key role of cell–cell distance. Nat. Rev. Microbiol. 2010, 8, 471–480. [CrossRef] [PubMed]
46. Sutherland, R.; Croydon, E.A.; Rolinson, G.N. Amoxycillin: A new semi-synthetic penicillin. Br. Med. J. 1972,
3, 13–16. [CrossRef] [PubMed]
47. Edwards, D.I. Mechanisms of selective toxicity of metronidazole and other nitroimidazole drugs. Br. J. Vener.
Dis. 1980, 56, 285–290. [CrossRef] [PubMed]
48. Sgolastra, F.; Petrucci, A.; Gatto, R.; Monaco, A. Effectiveness of Systemic Amoxicillin/Metronidazole as an
Adjunctive Therapy to Full-Mouth Scaling and Root Planing in the Treatment of Aggressive Periodontitis:
A Systematic Review and Meta-Analysis. J. Periodontol. 2012, 83, 731–743. [CrossRef]
49. Berglundh, T.; Krok, L.; Liljenberg, B.; Westfelt, E.; Serino, G.; Lindhe, J. The use of metronidazole and
amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial. J. Clin.
Periodontol. 1998, 25, 354–362. [CrossRef] [PubMed]
50. Cionca, N.; Giannopoulou, C.; Ugolotti, G.; Mombelli, A. Amoxicillin and metronidazole as an adjunct to
full-mouth scaling and root planing of chronic periodontitis. J. Periodontol. 2009, 80, 364–371. [CrossRef]
[PubMed]
51. Dahiya, P.; Kamal, R. Hyaluronic acid: A boon in periodontal therapy. N. Am. J. Med. Sci. 2013, 5, 309.
[CrossRef] [PubMed]
52. Adams, D.; Addy, M. Mouthrinses. Adv. Dent. Res. 1994, 8, 291–301. [CrossRef]
53. Goudouri, O.; Kontonasaki, E.; Lohbauer, U.; Boccaccini, A.R. Antibacterial properties of metal and metalloid
ions in chronic periodontitis and peri-implantitis therapy. Acta Biomater. 2014, 10, 3795–3810. [CrossRef]
[PubMed]
54. Chen, C.K.C.; Wilson, M.E. Eikenella corrodens in Human Oral and Non-Oral Infections: A Review.
J. Periodontol. 1992, 63, 941–953. [CrossRef]
55. Baghban, A.; Gupta, S. Parvimonas micra: A rare cause of native joint septic arthritis. Anaerobe 2016, 39,
26–27. [CrossRef]
56. Rams, T.E.; Feik, D.; Listgarten, M.A.; Slots, J. Peptostreptococcus micros in human periodontitis.
Oral Microbiol. Immunol. 1992, 7, 1–6. [CrossRef] [PubMed]
57. Santos, F.A.; Bastos, E.M.A.; Rodrigues, P.H.; de Uzeda, M.; de Carvalho, M.A.R.; de Macedo Farias, L.;
Andrade Moreira, E.S. Susceptibility of Prevotella intermedia/Prevotella nigrescens (and Porphyromonas
gingivalis) to Propolis (Bee Glue) and other Antimicrobial Agents. Anaerobe 2002, 8, 9–15. [CrossRef]
58. Han, Y.W. Fusobacterium nucleatum: A commensal-turned pathogen. Curr. Opin. Microbiol. 2015, 23,
141–147. [CrossRef] [PubMed]
59. Jacinto, R.C.; Montagner, F.; Signoretti, F.G.C.; Almeida, G.C.; Gomes, B.P.F.A. Frequency, Microbial
Interactions, and Antimicrobial Susceptibility of Fusobacterium nucleatum and Fusobacterium necrophorum
Isolated from Primary Endodontic Infections. J. Endod. 2008, 34, 1451–1456. [CrossRef]
60. Raja, M. Aggregatibacter Actinomycetemcomitans—A Tooth Killer? J. Clin. Diagn. Res. 2014, 8, 13–16.
[CrossRef] [PubMed]
61. Oettinger-Barak, O.; Dashper, S.G.; Catmull, D.V.; Adams, G.G.; Sela, M.N.; Machtei, E.E.; Reynolds, E.C.
Antibiotic susceptibility of Aggregatibacter actinomycetemcomitans JP2 in a biofilm. J. Oral Microbiol. 2013,
5, 20320. [CrossRef]
Pharmaceutics 2019, 11, 142 19 of 19
62. How, K.Y.; Song, K.P.; Chan, K.G. Porphyromonas gingivalis: An Overview of Periodontopathic Pathogen
below the Gum Line. Front. Microbiol. 2016, 7, 1–14. [CrossRef] [PubMed]
63. Jacinto, R.C.; Gomes, B.P.F.A.; Shah, H.N.; Ferraz, C.C.; Zaia, A.A.; Souza-Filho, F.J. Incidence and
antimicrobial susceptibility of Porphyromonas gingivalis isolated from mixed endodontic infections.
Int. Endod. J. 2006, 39, 62–70. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
